Skip to main content
Top
Published in: Medical Oncology 12/2014

01-12-2014 | Original Paper

Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies

Authors: Daye Cheng, Ying Sun, Hu He

Published in: Medical Oncology | Issue 12/2014

Login to get access

Abstract

In the past decade, several studies have suggested a possible link between circulating YKL-40 levels and endometrial carcinoma (EC), but have arrived at inconsistent results. Therefore, we conducted the present meta-analysis and aim to disclose a more comprehensive evaluation of the sensitivity, specificity, and diagnostic accuracy of YKL-40 in EC. We systematically searched PubMed, Embase, Web of Science, Science Direct, SpringerLink, EBSCO, Wanfang, and Chinese National Knowledge Infrastructure databases for studies that evaluated the diagnostic value of YKL-40 in endometrial cancer. The STATA software 12.0 and Meta-Disc software were used to test the heterogeneity and to evaluate the overall test performance. A total of seven studies including 234 EC cases and 300 controls were included in our meta-analysis. The summary estimates of YKL-40 for EC diagnosis indicated a moderately high diagnostic accuracy for circulating YKL-40, with a sensitivity of 0.74, a specificity of 0.87, a PLR of 5.74, a NLR of 0.30, a DOR of 19.14, and an AUC of 0.80. On the basis of our meta-analysis, therefore, circulating YKL-40 could be promising and meaningful in the diagnosis of EC.
Literature
1.
2.
go back to reference Dobrzycka B, Mackowiak-Matejczyk B, Kinalski M, Terlikowski SJ. Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma. Gynecol Oncol. 2013;128:454–60.PubMedCrossRef Dobrzycka B, Mackowiak-Matejczyk B, Kinalski M, Terlikowski SJ. Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma. Gynecol Oncol. 2013;128:454–60.PubMedCrossRef
3.
go back to reference Wittenberger T, Sleigh S, Reisel D, et al. DNA methylation markers for early detection of women’s cancer: promise and challenges. Epigenomics. 2014;6:311–27.PubMedCrossRef Wittenberger T, Sleigh S, Reisel D, et al. DNA methylation markers for early detection of women’s cancer: promise and challenges. Epigenomics. 2014;6:311–27.PubMedCrossRef
4.
go back to reference Renkema GH, Boot RG, Au FL, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem. 1998;251:504–9.PubMedCrossRef Renkema GH, Boot RG, Au FL, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem. 1998;251:504–9.PubMedCrossRef
5.
go back to reference Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem. 2003;278:37753–60.PubMedCrossRef Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem. 2003;278:37753–60.PubMedCrossRef
6.
go back to reference Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221–5.PubMedCrossRef Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221–5.PubMedCrossRef
7.
go back to reference Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172–209.PubMed Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172–209.PubMed
9.
go back to reference Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother. 2014;63:11–20.PubMedCrossRef Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother. 2014;63:11–20.PubMedCrossRef
10.
go back to reference Johansen JS, Baslund B, Garbarsch C, et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 1999;42:2624–30.PubMedCrossRef Johansen JS, Baslund B, Garbarsch C, et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 1999;42:2624–30.PubMedCrossRef
11.
go back to reference Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15:194–202.PubMedCrossRef Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15:194–202.PubMedCrossRef
12.
go back to reference Liu X, Zhang Y, Zhu Z, Ha M, Wang Y. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer. Med Oncol. 2014;31:85.PubMedCrossRef Liu X, Zhang Y, Zhu Z, Ha M, Wang Y. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer. Med Oncol. 2014;31:85.PubMedCrossRef
13.
go back to reference Tschirdewahn S, Reis H, Niedworok C, et al. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urol Oncol. 2014;32:663–9.PubMedCrossRef Tschirdewahn S, Reis H, Niedworok C, et al. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urol Oncol. 2014;32:663–9.PubMedCrossRef
14.
go back to reference Schultz NA, Christensen IJ, Werner J, et al. Diagnostic and prognostic impact of circulating YKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer. PLoS One. 2013;8:e67059.PubMedCentralPubMedCrossRef Schultz NA, Christensen IJ, Werner J, et al. Diagnostic and prognostic impact of circulating YKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer. PLoS One. 2013;8:e67059.PubMedCentralPubMedCrossRef
15.
go back to reference Wang D, Zhai B, Hu F, et al. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One. 2012;7:e51127.PubMedCentralPubMedCrossRef Wang D, Zhai B, Hu F, et al. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One. 2012;7:e51127.PubMedCentralPubMedCrossRef
16.
17.
go back to reference Fan JT, Li MJ, Shen P, et al. Serum and tissue level of YKL-40 in endometrial cancer. Eur J Gynaecol Oncol. 2014;35:304–8.PubMed Fan JT, Li MJ, Shen P, et al. Serum and tissue level of YKL-40 in endometrial cancer. Eur J Gynaecol Oncol. 2014;35:304–8.PubMed
18.
go back to reference Peng C, Peng J, Jiang L, et al. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res. 2010;38:1448–57.PubMedCrossRef Peng C, Peng J, Jiang L, et al. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res. 2010;38:1448–57.PubMedCrossRef
19.
go back to reference Thom I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer. 2010;116:4114–21.PubMedCrossRef Thom I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer. 2010;116:4114–21.PubMedCrossRef
20.
go back to reference Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.PubMedCentralPubMedCrossRef Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.PubMedCentralPubMedCrossRef
22.
go back to reference Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef
24.
go back to reference Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007;104:435–42.PubMedCrossRef Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007;104:435–42.PubMedCrossRef
25.
go back to reference Fan JT, Si XH, Liao Y, Shen P. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer. Arch Gynecol Obstet. 2013;287:111–5.PubMedCrossRef Fan JT, Si XH, Liao Y, Shen P. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer. Arch Gynecol Obstet. 2013;287:111–5.PubMedCrossRef
26.
go back to reference Si XH, Fan J, Liao Y, et al. Preliminary research of serum YKL-40 in the diagnosis of endometrial carcinoma. J Pract Gynecol. 2011;27:121–4. Si XH, Fan J, Liao Y, et al. Preliminary research of serum YKL-40 in the diagnosis of endometrial carcinoma. J Pract Gynecol. 2011;27:121–4.
27.
go back to reference Zhang X, Yang C, Lv J. Expression and significance of serum HE4 and YKL-40 in patients with endometrial cancer. Progress Obstet Gynecol. 2011;20:377–80. Zhang X, Yang C, Lv J. Expression and significance of serum HE4 and YKL-40 in patients with endometrial cancer. Progress Obstet Gynecol. 2011;20:377–80.
28.
go back to reference Wei P. Expression and clinical significance of YKL-40 in endometrial carcinoma. Peking: Peking Union Medical College; 2011. Wei P. Expression and clinical significance of YKL-40 in endometrial carcinoma. Peking: Peking Union Medical College; 2011.
29.
go back to reference Geng X. The research of YKL-40 and CA125 in diagnosis of endometrial carcinoma. Guangxi: Guangxi Medical University; 2011. Geng X. The research of YKL-40 and CA125 in diagnosis of endometrial carcinoma. Guangxi: Guangxi Medical University; 2011.
30.
go back to reference Yu M. The preliminary investigation of YKL-40 in the diagnosis of endometrial carcinoma. Sichuan: Sichuan University; 2007. Yu M. The preliminary investigation of YKL-40 in the diagnosis of endometrial carcinoma. Sichuan: Sichuan University; 2007.
31.
go back to reference Chung HH, Kim JW, Park NH, et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006;85:1501–5.PubMedCrossRef Chung HH, Kim JW, Park NH, et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006;85:1501–5.PubMedCrossRef
32.
go back to reference Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203(228):e1–6. Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203(228):e1–6.
33.
go back to reference Mitsuhashi A, Matsui H, Usui H, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20:71–7.PubMedCrossRef Mitsuhashi A, Matsui H, Usui H, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20:71–7.PubMedCrossRef
34.
go back to reference Chudecka-Glaz AM, Cymbaluk-Ploska AA, Menkiszak JL, et al. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res. 2014;7:62.PubMedCentralPubMedCrossRef Chudecka-Glaz AM, Cymbaluk-Ploska AA, Menkiszak JL, et al. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res. 2014;7:62.PubMedCentralPubMedCrossRef
35.
go back to reference Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.PubMedCrossRef Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.PubMedCrossRef
Metadata
Title
Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies
Authors
Daye Cheng
Ying Sun
Hu He
Publication date
01-12-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 12/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0326-8

Other articles of this Issue 12/2014

Medical Oncology 12/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine